well as a decline in mental and cognitive abilities.
Although current treatments, primarily levodopa combined with carbidopa, help alleviate these symptoms by compensating for the dopamine deficiency and improving motor functions, their effectiveness declines with long-term use, and unpleasant side effects such as motor fluctuations and involuntary movements may appear. This has prompted researchers to search for adjunctive treatments that can enhance the effect of standard treatment and reduce these complications.
In this context, a research team from the University of Guadalajara in Mexico decided to explore the possibility of using bee venom as an adjunctive therapy, based on its containing biologically active compounds such as melittin, phospholipase A2, and apamin, which previous studies have shown to have anti-inflammatory and antioxidant properties, as well as positive effects on the nervous system.
The study found that bee venom can enhance the effectiveness of standard treatment for Parkinson's disease, after experiments on mice showed a significant improvement in motor and cognitive performance when combined with the drug levodopa/carbidopa, opening up a promising field for developing adjunctive treatments for this chronic neurological disorder.
In a systematic step to test their hypothesis, the researchers used an animal model followed in neurological studies, which involves injecting male CD-1 mice with a chemical known as "6-hydroxydopamine," which causes damage to dopamine-producing cells, thus mimicking what happens in the human brain of people with Parkinson's disease.
They then divided the mice into four groups: a healthy group that did not contract the disease, a group that was infected but not treated, a group that received standard treatment (levodopa/carbidopa), and a fourth group that received standard treatment plus freeze-dried bee venom.
The treatment lasted for 18 days, from day 13 to day 30 after the lesion was induced, and then all mice underwent motor and cognitive tests including the drum test, foot pull test, new object recognition test, and sideways passage test.
The results showed that the mice that received bee venom in addition to the standard treatment showed significant improvement in several aspects compared to the other groups. Specifically, in terms of motor skills, these mice maintained better coordination in their forelimbs and exhibited less foot drag, indicating improved motor performance compared to those that received the standard treatment alone.
From a cognitive standpoint, in memory tests, the mice treated with bee venom retained their ability to recognize new objects, while the other groups continued to show cognitive deficits. The group receiving the combined treatment also demonstrated the strongest improvement in lateral motor skills in the lateral passage test.
However, the researchers acknowledge a significant limitation of their study: it focused solely on assessing behavioral outcomes, without directly examining the survival of dopaminergic neurons or measuring molecular markers of inflammation and oxidative stress that might explain the underlying biological mechanisms of these improvements. For this reason, the study's lead author, Professor Alma Karen Lumilli-Liebe, emphasizes that their findings suggest promising behavioral benefits of bee venom as an adjunct therapy, but underscores the urgent need for further research to understand the precise mechanisms by which this venom works.
Although there is still a long way to go before this treatment can be applied to humans, these results open the door of hope to a promising field for the development of new supportive therapies that could make a real difference in the lives of millions of people with Parkinson's disease around the world, especially those who are experiencing a decline in their response to standard treatment or its side effects.
